RGNX
Regenxbio Inc

2,535
Mkt Cap
$688M
Volume
178,554.00
52W High
$13.93
52W Low
$5.04
PE Ratio
-3.93
RGNX Fundamentals
Price
$13.32
Prev Close
$13.62
Open
$13.57
50D MA
$10.15
Beta
1.61
Avg. Volume
487,646.38
EPS (Annual)
-$4.59
P/B
3.21
Rev/Employee
$236,056.66
Loading...
Loading...
News
all
press releases
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Oct. 15, 2025 ROCKVILLE, Md., Oct. 15, 2025...
PR Newswire·13d ago
News Placeholder
More News
News Placeholder
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting PR Newswire...
PR Newswire·19d ago
News Placeholder
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Zacks·2mo ago
News Placeholder
Are Options Traders Betting on a Big Move in Regenxbio Stock?
Investors need to pay close attention to RGNX stock based on the movements in the options market lately.
Zacks·3mo ago
News Placeholder
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -22.12% and -21.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
Zacks·6mo ago
News Placeholder
Biotech stocks jump as Makary outlines FDA vision, RBC comments
Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.
investing.com·6mo ago
News Placeholder
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., Feb. 25, 2025 ROCKVILLE, Md., Feb. 25, 2025...
PR Newswire·8mo ago
News Placeholder
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025
REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025 PR Newswire ROCKVILLE, Md...
PR Newswire·9mo ago

Latest RGNX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.